Trazodone Hydrochloride Tablets Usp shortage — IT supply status & alternatives

Trazodone Hydrochloride Tablets Usp

—

In supply · Australia

In supply · 🇦🇺 Australia · short in🇺🇸 US🇮🇹 IT

In supply in Australia

Reading today’s signals…

✓ Can I substitute?

In supply

no shortage substitution needed

⇄ Best alternative

None listed

refer to prescriber

◷ Expected back

No estimate

No estimate provided

Product attributes reference data we hold

Active ingredient (INN)	Trazodone Hydrochloride Tablets Usp
Therapeutic category	Auto-created by FDA Drug Enforcement — Full Recall Database scraper

Controlled substance	No

Patient information leaflet (PIL)	Not on file

Summary of product characteristics (SPC)	Not on file

Trade price 🇦🇺 Australia · awaiting price ingest

🇦🇺 AU

Ex-manufacturer

—

Dispensed (DPMQ)

—

Pack

—

Not yet captured for Australia

Official pricing isn’t on file for this market yet. PBS (Australia), NHS Drug Tariff (United Kingdom) and CMS NADAC (United States) feeds are prioritised; this panel populates automatically once the data lands.

Substitution pathways 🇦🇺 Australia · TGA

—

No substitution instrument in force

Dispense per normal rules, or refer to the prescriber. No active SSSI/S19A instrument detected for this medicine.

Shortage status by regulator official notices

🇺🇸

United States

ANSM Ruptures · 1mo ago

High

🇮🇹

Italy

AIFA · 2d ago

Medium

Recalls official enforcement reports

🇺🇸

Trazodone Hydrochloride Tablets Usp

AVKARE Inc. · Dec 2020

Class Idetails ↗

Verified timeline regulator events

🇮🇹 15 Mar 2026

medium reported

🇺🇸 7 Dec 2020

high reported

🇮🇹 31 Dec 2015

Shortage resolved

Sources official regulators

🇮🇹

AIFA

verified 2d ago

verify ↗

🇺🇸

ANSM Ruptures

verified 1mo ago

verify ↗

Mederti Drug Report

Generated 4 July 2026 · Australia market · 2 regulatory sources

For health-professional reference only. Mederti aggregates shortage and substitution information from official regulatory sources. It is not clinical advice and data may be incomplete or delayed. Confirm any substitution or supply decision against the primary regulator source, the prescriber, and current clinical references (e.g. AMH) before acting. Terms.